Identification of the urokinase receptor as an adhesion receptor for vitronectin
- PMID: 7528215
Identification of the urokinase receptor as an adhesion receptor for vitronectin
Abstract
Urokinase receptors, expressed on surfaces of many cell types, focus to the pericellular space plasminogen-dependent proteolysis important in matrix remodeling and cell movement. We now report that the urokinase receptor (uPAR) is also a high affinity (Kd < 30 nM) receptor for vitronectin. Recombinant uPAR binds vitronectin in the absence of urokinase, but vitronectin binding is promoted by concurrent receptor binding of either urokinase or fragments thereof containing its uPAR binding domain. Stable epithelial cell transfectants expressing membrane-anchored uPAR, but not cells expressing soluble uPAR, become strongly adhesive with altered morphology in the absence of urokinase. These observations identify a new class of vitronectin receptor and imply a duality in function for the receptor that intrinsically links matrix adhesion to regulation of protease activity. Increases in urokinase receptor expression known to be associated with cellular activation and malignant transformation could modulate cellular trafficking and function by promoting attachment to vitronectin.
Similar articles
-
A composite role of vitronectin and urokinase in the modulation of cell morphology upon expression of the urokinase receptor.J Biol Chem. 2008 May 30;283(22):15217-23. doi: 10.1074/jbc.C700214200. Epub 2008 Mar 24. J Biol Chem. 2008. PMID: 18362146 Free PMC article.
-
Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy.J Biol Chem. 1994 May 20;269(20):14746-50. J Biol Chem. 1994. PMID: 7514182
-
Vitronectin binding to urokinase receptor in human breast cancer.Clin Cancer Res. 1997 Aug;3(8):1299-308. Clin Cancer Res. 1997. PMID: 9815812
-
Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor.Curr Pharm Des. 2003;9(19):1499-528. doi: 10.2174/1381612033454630. Curr Pharm Des. 2003. PMID: 12871065 Review.
-
Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.Stem Cells. 1997;15(6):398-408. doi: 10.1002/stem.150398. Stem Cells. 1997. PMID: 9402652 Review.
Cited by
-
Small-molecule inhibition of the uPAR·uPA interaction: synthesis, biochemical, cellular, in vivo pharmacokinetics and efficacy studies in breast cancer metastasis.Bioorg Med Chem. 2013 Apr 1;21(7):2145-55. doi: 10.1016/j.bmc.2012.12.047. Epub 2013 Jan 9. Bioorg Med Chem. 2013. PMID: 23411397 Free PMC article.
-
Regulation of Rac1 activation by the low density lipoprotein receptor-related protein.J Cell Biol. 2002 Dec 23;159(6):1061-70. doi: 10.1083/jcb.200207070. Epub 2002 Dec 23. J Cell Biol. 2002. PMID: 12499359 Free PMC article.
-
The Urokinase Plasminogen Activation System in Pancreatic Cancer: Prospective Diagnostic and Therapeutic Targets.Biomolecules. 2022 Jan 18;12(2):152. doi: 10.3390/biom12020152. Biomolecules. 2022. PMID: 35204653 Free PMC article. Review.
-
Antagonistic anti-urokinase plasminogen activator receptor (uPAR) antibodies significantly inhibit uPAR-mediated cellular signaling and migration.J Biol Chem. 2010 Aug 27;285(35):26878-26888. doi: 10.1074/jbc.M109.077677. Epub 2010 May 25. J Biol Chem. 2010. PMID: 20501655 Free PMC article.
-
Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours.Br J Cancer. 2001 Jul 6;85(1):85-92. doi: 10.1054/bjoc.2001.1867. Br J Cancer. 2001. PMID: 11437407 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical